Fifty million Americans wake up in chronic pain every day. Not soreness. Not the dull ache of a hard week. Pain that has dismantled careers, ended marriages, and driven people, my patients, over 25 years, to suicide, overdose, and a slow erasure of self. I trained at USC and UCLA, spent three decades in interventional pain management, and I can tell you with clinical certainty: the system we built to treat these patients has been a catastrophe. It flooded the country with opioids, then strangled the pipeline without a replacement, leaving patients stranded in a no-man’s land between addiction clinics and physicians afraid to prescribe.

Now two powerful forces are converging on chronic pain from opposite directions. One emerged through metabolic medicine. The other is attempting to rewire the brain directly. They are barely talking to each other. That is about to change, and the collision that follows will define the next generation of pain treatment.

Semaglutide was designed to lower blood sugar and reduce body weight. It does both. But physicians and patients noticed something else: chronic pain was improving. Not universally, not in every condition, but in ways that weight loss alone cannot explain. A landmark RCT published in the New England Journal of Medicine demonstrated that once-weekly semaglutide reduced knee osteoarthritis pain scores by nearly 15 additional points over placebo with meaningful gains in physical function that persisted after controlling for weight reduction. GLP-1 receptors are expressed throughout the central nervous system, in the cortex, hypothalamus, and spinal cord, and semaglutide has been shown in preclinical models to suppress neuroinflammation directly, independent of any glycemic effect. A 2025 systematic review from Mayo Clinic characterized GLP-1 receptor agonists as a potential “game changer” in pain management, operating through macrophage repolarization, dopaminergic modulation, and direct nociceptive receptor suppression. We may be treating pain through mechanisms we have not yet fully mapped. That is not a problem to dismiss. It is a signal to explore.

Across the clinical divide, an entirely different industry has reached a different conclusion: chronic pain is a brain disorder, not a peripheral one. Decades of functional MRI confirm that chronic pain reorganizes central processing, altering connectivity in the insula, anterior cingulate, and prefrontal cortex, and amplifying signals that should have resolved. The concept of central sensitization has moved from theoretical neuroscience into mainstream clinical framing. Maladaptive neuroplasticity sustains pain long after tissue has healed, and because neuroplasticity is activity-dependent, it can in principle be reversed. That reversibility is the entire commercial wager of the neurotechnology sector. Closed-loop neuromodulation, AI-guided spinal cord stimulation, transcranial magnetic stimulation. These tools do not dampen inflammation. They attempt to correct the brain’s faulty amplification of pain at its source. Machine learning algorithms are now predicting spinal cord stimulation outcomes preoperatively and identifying neural biomarkers that distinguish responders from non-responders.

Here is the confrontation neither industry is advertising: they are competing for the same patient. GLP-1 therapies carry the infrastructure of a pharmaceutical juggernaut with global manufacturing, established reimbursement, household-name brand recognition. Neurotechnology is venture-funded, faster-moving, less standardized, and unconstrained by the conservatism of the pharmacy benefit. Chronic pain represents a $635 billion annual burden in U.S. lost productivity and health care costs. Whoever can demonstrate durable, measurable pain reduction will not just gain market share. They will set the standard of care and control how pain is defined, coded, reimbursed, and treated for the next 20 years.

The danger is not that one paradigm wins. It is that it wins completely and we repeat the pathology we know too well. Chronic pain is not one disease. It is a multi-system disorder in which neuroinflammation, metabolic dysregulation, gut-brain signaling, mitochondrial dysfunction, and altered central processing interact across pathways that our specialty silos were never designed to address simultaneously. We declared pain an opioid-deficiency state in the 1990s. We know how that story ends. The same reductionism applied to either metabolic or neural models will produce the same structural failure. A powerful partial truth scaled into a universal protocol, and millions of patients who don’t fit the model left behind. The biology does not respect our categories. Metabolism shapes neural architecture. Neuroinflammation dysregulates insulin signaling. GLP-1 receptors in the spinal cord and the gut-brain axis occupy the same territory that closed-loop stimulators are targeting from above. These are not competing explanations. They are different windows into the same system.

After 25 years and over 10,000 patients, I am not waiting for a single breakthrough to solve this. I am watching two industries circle a problem that requires both of them, and a clinical framework sophisticated enough to deploy them in combination, matched to individual biology, accessible to the patients who have already been failed once. That framework does not yet exist at scale. Building it is the argument. The collision between GLP-1 pharmacology and neurotechnology is coming whether we are ready or not. The only question is whether clinicians, and not investors, not insurers, not algorithms, will be at the table when the standard of care is written.

Amir Friedman is a pain management physician.